ACE and colorectal cancer: Likewise, in analyses using SBP SNPs in ACE, genetically proxied SBP lowering via ACE inhibition was associated with an increased odds of colorectal cancer (OR equivalent to 1 mm Hg lower SBP: 1.11, 95% CI 1.04 to 1.18; P = 1.3 × 10−3).